Breast cancer is the most common cancer in Australian women (excluding non-melanoma skin cancer), accounting for 28.2 per cent of all new cancers in women. 36 women are diagnosed in Australia every day. The Oncotype DX test is a 21 gene assay that predicts the patient’s likely benefit from chemotherapy and their risk of breast cancer recurrence to inform adjuvant treatment decisions in certain women with early stage invasive breast cancer. It costs $AUS3900 and no Medicare rebate is currently available. This hugely expensive test can be crucial in making life saving treatment decisions and should be fully funded by Medicare as it could save thousands of women from having unnecessary chemotherapy with the associated toxicity risks, stress and expense.